## **Product** Data Sheet

### Anti-neurodegeneration agent 1

Cat. No.: HY-U00314 CAS No.: 289893-23-8 Molecular Formula:  $C_{14}H_{20}CIN_3O_3$ 

Molecular Weight: 313.78

Target: Others

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

# OF NOOH N

#### **BIOLOGICAL ACTIVITY**

Description

Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.

In Vivo

In Anti-neurodegeneration agent 1 (Compound I)-treated mSODl<sup>(G93A)</sup> mice, Western blot analysis reveals an observable 'band shift' of HSF-I, indicative of a stress-induced activation of HSF-I by hyper-phosphorylation. Immunostaining reveals that, at 120 days of age, expression of Hsp70 and Hsp90 is increased in the lumbar spinal cords of both untreated and Antineurodegeneration agent 1- treated SOD1<sup>(G93A)</sup> mice, although there is a clear increase in the intensity of Hsp70 and Hsp90 immunoreactivity in motor neurons of Anti-neurodegeneration agent 1-treated mSODl<sup>(G93A)</sup> mice. Anti-neurodegeneration agent I- treated mice live an average of 153 days (±2.6 SEM, n=7). This represents a significant increase in lifespan of over 22% (p=<0.001). The effect of beginning Anti-neurodegeneration agent 1 treatment at the time of disease onset is also tested by starting treatment at 70 days of age, when the first signs of locomotor defects are observed. Anti-neurodegeneration agent 1 treatment from 70 days of age extended the mean lifespan of mSODl<sup>(G93A)</sup> mice by 23 days, from 125 days (±1.8 SEM, n=18) in the untreated group to 148 days (±1.5 SEM, n=5) in the treated group. This represents an increase in lifespan of 18% (p=<0.001)<sup>[1]</sup>

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **PROTOCOL**

Animal
Administration [1]

Mice<sup>[1]</sup>

Transgenic mice over-expressing human mutant SODI are used. Anti-neurodegeneration agent 1 is tested for the ability to prevent the progressive loss of motor neurons and muscle function known to occur in mSODI<sup>(G93A)</sup> mice. mSODI<sup>(G93A)</sup> mice of both sexes are treated daily with Anti-neurodegeneration agent 1 (10 mg/kg, ip) from 35 or 70 days of age<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. BARBER, Jack R. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH NEURODEGENERATION. W02008039514A1.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com